Cargando…

Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients

Heavy alcohol consumption can cause hyperhomocysteinemia, which could be consequential in the proinflammatory response and worsening of the neurobehavioral domains of alcohol use disorder (AUD), such as alcohol withdrawal. We examined the role of heavy drinking, hyperhomocysteinemia, gut dysfunction...

Descripción completa

Detalles Bibliográficos
Autores principales: Vatsalya, Vatsalya, Gala, Khushboo S., Hassan, Ammar Z., Frimodig, Jane, Kong, Maiying, Sinha, Nachiketa, Schwandt, Melanie L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823569/
https://www.ncbi.nlm.nih.gov/pubmed/33374263
http://dx.doi.org/10.3390/biomedicines9010007
_version_ 1783639866832060416
author Vatsalya, Vatsalya
Gala, Khushboo S.
Hassan, Ammar Z.
Frimodig, Jane
Kong, Maiying
Sinha, Nachiketa
Schwandt, Melanie L.
author_facet Vatsalya, Vatsalya
Gala, Khushboo S.
Hassan, Ammar Z.
Frimodig, Jane
Kong, Maiying
Sinha, Nachiketa
Schwandt, Melanie L.
author_sort Vatsalya, Vatsalya
collection PubMed
description Heavy alcohol consumption can cause hyperhomocysteinemia, which could be consequential in the proinflammatory response and worsening of the neurobehavioral domains of alcohol use disorder (AUD), such as alcohol withdrawal. We examined the role of heavy drinking, hyperhomocysteinemia, gut dysfunction and inflammation in early-stage alcoholic liver disease (ALD) in AUD patients. A total of 110 AUD patients without clinical manifestations of liver injury were grouped by the serum homocysteine levels (SHL): normal ≤ 13 µmol/L (Group 1 (Gr.1); n = 80), and elevated > 13 µmol/L (Group 2 (Gr.2), n = 30). A comprehensive metabolic panel, SHL, a nutritional assessment, and drinking history assessed by the timeline followback questionnaire were evaluated. A subset analysis was performed on 47 subjects (Gr.1 n = 27; Gr.2 n = 20) for additional measures: Clinical Institute Withdrawal Assessment for Alcohol (CIWA) score, plasma cytokines (interleukin-1β (IL-1β)), gut dysfunction markers (lipopolysaccharide (LPS), and LPS-binding protein (LBP)); 27% of the AUD patients exhibited hyperhomocysteinemia. SHL was significantly associated (p = 0.034) with heavy drinking days (HDD90). Subset analyses showed that the withdrawal ratings were both clinically and statistically (p = 0.033) elevated and significantly associated with hyperhomocysteinemia (p = 0.016) in Gr.2. LBP, IL1-β, SHL, and HDD90 showed significant cumulative effects (adjusted R(2) = 0.627) on withdrawal ratings in Gr.2 subset. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were significantly higher in all Gr.2 patients; AUROC showed a fair level of true positivity for ALT (0.676), and AST (0.686). Il1-β, LBP, SHL, and HDD90 showed significant cumulative effects (adjusted R(2) = 0.554) on the elevated ALT in Gr.2 subset as well. The gut-brain derived proinflammatory response, patterns of heavy drinking, and hyperhomocysteinemia were closely associated with clinically elevated alcohol withdrawal and elevated liver injury. Hyperhomocysteinemia could have a potential phenotypic marker response indicative of early-stage ALD along with AUD.
format Online
Article
Text
id pubmed-7823569
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78235692021-01-24 Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients Vatsalya, Vatsalya Gala, Khushboo S. Hassan, Ammar Z. Frimodig, Jane Kong, Maiying Sinha, Nachiketa Schwandt, Melanie L. Biomedicines Article Heavy alcohol consumption can cause hyperhomocysteinemia, which could be consequential in the proinflammatory response and worsening of the neurobehavioral domains of alcohol use disorder (AUD), such as alcohol withdrawal. We examined the role of heavy drinking, hyperhomocysteinemia, gut dysfunction and inflammation in early-stage alcoholic liver disease (ALD) in AUD patients. A total of 110 AUD patients without clinical manifestations of liver injury were grouped by the serum homocysteine levels (SHL): normal ≤ 13 µmol/L (Group 1 (Gr.1); n = 80), and elevated > 13 µmol/L (Group 2 (Gr.2), n = 30). A comprehensive metabolic panel, SHL, a nutritional assessment, and drinking history assessed by the timeline followback questionnaire were evaluated. A subset analysis was performed on 47 subjects (Gr.1 n = 27; Gr.2 n = 20) for additional measures: Clinical Institute Withdrawal Assessment for Alcohol (CIWA) score, plasma cytokines (interleukin-1β (IL-1β)), gut dysfunction markers (lipopolysaccharide (LPS), and LPS-binding protein (LBP)); 27% of the AUD patients exhibited hyperhomocysteinemia. SHL was significantly associated (p = 0.034) with heavy drinking days (HDD90). Subset analyses showed that the withdrawal ratings were both clinically and statistically (p = 0.033) elevated and significantly associated with hyperhomocysteinemia (p = 0.016) in Gr.2. LBP, IL1-β, SHL, and HDD90 showed significant cumulative effects (adjusted R(2) = 0.627) on withdrawal ratings in Gr.2 subset. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were significantly higher in all Gr.2 patients; AUROC showed a fair level of true positivity for ALT (0.676), and AST (0.686). Il1-β, LBP, SHL, and HDD90 showed significant cumulative effects (adjusted R(2) = 0.554) on the elevated ALT in Gr.2 subset as well. The gut-brain derived proinflammatory response, patterns of heavy drinking, and hyperhomocysteinemia were closely associated with clinically elevated alcohol withdrawal and elevated liver injury. Hyperhomocysteinemia could have a potential phenotypic marker response indicative of early-stage ALD along with AUD. MDPI 2020-12-24 /pmc/articles/PMC7823569/ /pubmed/33374263 http://dx.doi.org/10.3390/biomedicines9010007 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vatsalya, Vatsalya
Gala, Khushboo S.
Hassan, Ammar Z.
Frimodig, Jane
Kong, Maiying
Sinha, Nachiketa
Schwandt, Melanie L.
Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients
title Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients
title_full Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients
title_fullStr Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients
title_full_unstemmed Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients
title_short Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients
title_sort characterization of early-stage alcoholic liver disease with hyperhomocysteinemia and gut dysfunction and associated immune response in alcohol use disorder patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823569/
https://www.ncbi.nlm.nih.gov/pubmed/33374263
http://dx.doi.org/10.3390/biomedicines9010007
work_keys_str_mv AT vatsalyavatsalya characterizationofearlystagealcoholicliverdiseasewithhyperhomocysteinemiaandgutdysfunctionandassociatedimmuneresponseinalcoholusedisorderpatients
AT galakhushboos characterizationofearlystagealcoholicliverdiseasewithhyperhomocysteinemiaandgutdysfunctionandassociatedimmuneresponseinalcoholusedisorderpatients
AT hassanammarz characterizationofearlystagealcoholicliverdiseasewithhyperhomocysteinemiaandgutdysfunctionandassociatedimmuneresponseinalcoholusedisorderpatients
AT frimodigjane characterizationofearlystagealcoholicliverdiseasewithhyperhomocysteinemiaandgutdysfunctionandassociatedimmuneresponseinalcoholusedisorderpatients
AT kongmaiying characterizationofearlystagealcoholicliverdiseasewithhyperhomocysteinemiaandgutdysfunctionandassociatedimmuneresponseinalcoholusedisorderpatients
AT sinhanachiketa characterizationofearlystagealcoholicliverdiseasewithhyperhomocysteinemiaandgutdysfunctionandassociatedimmuneresponseinalcoholusedisorderpatients
AT schwandtmelaniel characterizationofearlystagealcoholicliverdiseasewithhyperhomocysteinemiaandgutdysfunctionandassociatedimmuneresponseinalcoholusedisorderpatients